Nav: Home

Scientists compared ways of drug delivery to malignant tumors

April 08, 2019

A team of biologists from Sechenov First Moscow State Medical University and Lobachevsky University (Nizhny Novgorod) analyzed available methods of targeted drug delivery to malignant tumors. Individual approaches to cancer therapy limit the influence of drugs on healthy tissues and reduce side effects. The results of the study were published in the Cancers journal. The research was supported by a grant issued by the Ministry of Science and Higher Education .

The difference between healthy tissue and a tumor lies in the structure of its vasculature and changes in metabolism. In tumors blood vessels are formed chaotically, have different shapes and diameters, and exhibit closed ends and protrusions. The structure of lymphatic vessels also changes. A tumor and its vasculature grow at different speed causing oxygen and nutrients deficiency. The structure of the tissue and its metabolism changes, as well as the profile of molecules on the surface of tumor cells, and the cancer progresses. Taking these facts into consideration, one can develop methods of target antitumor drugs delivery without affecting healthy cells and causing unnecessary side effects.

Currently, there are three main ways of targeted drug-to-tumor delivery: passive targeting that takes into account the structure of the vessels; active targeting in which an antitumor drug binds with a molecular target; and cell-mediated targeting.

Due to the peculiarities of tumor vessels, large molecules can enter them relatively easily and accumulate in the tumor tissue. This phenomenon is known as enhanced permeability and retention effect, and passive drug targeting is based on it. However, this delivery method doesn't always guarantee a desired effect. To increase its efficiency, individual therapies are developed on the basis of tumor characteristics. For example, the size of an agent may be optimized accordingly.

Active targeting complements the passive method. It increases the accumulation of a drug in tumor and the time of its retention. In their earlier work the team presented a multifunctional complex that leads to a synergistic effect of combined chemo- and radiotherapy agents. The base of the complex is a luminescent nanoparticle that contains a radioactive isotope 90Y used in radionuclide therapy. On the surface there is a bound highly active fragment of exotoxin A obtained from Pseudomonas aeruginosa (PE40). The complex binds with a marker protein of cancer cells, and its toxic agents affect the tumor. This treatment method works because tumor cells have different metabolism and molecular profiles than the cells of healthy tissues.

Certain types of cells are able to penetrate tumor tissues and therefore can also be used to deliver drugs. Cell-mediated targeting extends the washout period, controls the release of the drug, and reduces general toxicity and side effects. This method has its limitations, but it is also very promising.

"Having a choice between various treatment methods that take into account molecular and structural characteristics of a tumor and being able to adjust drug administration regime means approaching the goals of personalized medicine," said Irina Balalayeva, a Candidate of Biological Sciences, Dean of the Department of Biophysics of the Institute of Biology and Biomedicine at Lobachevsky University, and a senior research associate of the laboratory of nanotheranostics at the Institute of Molecular Medicine, Sechenov Moscow State Medical University.

Understanding the processes of nutrients and metabolic products transportation within a tumor, the peculiarities of its structure, and its interaction with immune system cells can help increase the efficiency of antitumor drug delivery and cancer treatment.

Sechenov University

Related Tumor Cells Articles:

When healthy cells stimulate the migration of tumor cells
Estrogens act as a driving force of both healthy and cancerous mammary cell growth by binding to receptors that include GPER, which is generally located in cell membranes.
Tumor cells get stiff before becoming invasive
A study published now on Nature Communications shows that breast cancer cells undergo a stiffening state prior to acquiring malignant features and becoming invasive.
Tumor-trained T cells go on patrol
In cancer, immune cells infiltrate tumors -- but it hasn't been known which immune cells exit the tumor or where they go next.
Tumor-dwelling immune cells thwart cancer immunotherapy
Researchers have caught tumor-associated immune cells called macrophages in the act of stealing checkpoint inhibitor antibodies away from their intended T cell targets, and blocking this thievery led to improved therapeutic responses in tumor-bearing mice.
Are tumor cells glutamine addicts?
Many tumors are thought to depend on glutamine, suggesting glutamine deprivation as therapeutic approach, but a new study shows that this effect might have been overestimated.
Tethered nanoparticles make tumor cells more vulnerable
MIT researchers have devised a way to make cancer cells more susceptible to certain types of cancer treatment, by coating the cells with nanoparticles before delivering drugs.
Researchers create viruses to selectively attack tumor cells
It is an innovative approach that takes advantage of the different expression profiles of certain proteins between tumor and healthy cells that make the virus to only infect the first ones.
Scientists use tumor-derived dendritic cells to slow tumor growth
In the human body, so-called dendritic cells are responsible for activating our immune system.
Tumor cells are dependent on fat to start metastasis
A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Nature identifies metastasis-initiating cells through a specific marker, namely the protein CD36.
Once inside a tumor, our immune cells become traitors
New research has found a subset of our immune cells (called regulatory T cells) that are highly abundant in the tumor microenvironment and are particularly good at suppressing the anticancer immune response.

Related Tumor Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".